Long-term outcome of living-donor liver transplantation for combined hepatocellular-cholangiocarcinoma

Shinji Itoh; Toru Ikegami; Tomoharu Yoshizumi; Huanlin Wang; Kazuki Takeishi; Norifumi Harimoto; Yo Ichi Yamashita; Hirofumi Kawanaka; Shinichi Aishima; Ken Shirabe; Yoshihiko Maehara

Long-term outcome of living-donor liver transplantation for combined hepatocellular-cholangiocarcinoma

Shinji Itoh, Toru Ikegami, Tomoharu Yoshizumi, Huanlin Wang, Kazuki Takeishi, Norifumi Harimoto, Yo Ichi Yamashita, Hirofumi Kawanaka, Shinichi Aishima, Ken Shirabe, Yoshihiko Maehara

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Background/Aim: Combined hepatocellular-cholangio carcinoma (cHC-CC) is found unexpectedly in explanted or resected liver specimens. The current study evaluated the longterm outcomes of living-donor liver transplantation (LDLT) between patients with cHC-CC and hepatocellular carcinoma (HCC). Patients and Methods: We performed 178 LDLT including 8 patients of pathologically and immunohistochemically diagnosed cHC-CC who all under went LDLT with a preoperative diagnosis of HCC by ima ging study. Results: Out of the 8 patients, 6 were within the Milan criteria and all were within the Kyushu University criteria. The 1-, 5- and 10-year overall survival (OS) and disease-free survival (DFS) rates after LDLT for patients with cHC-CC were 87.5, 72.9 and 48.6% and 85.7, 85.7 and 85.7%, respectively. The OS and DFS between patients with cHC-CC and HCC were not statistically different. Conclusion: LDLT for patients with cHC-CC using the Milan criteria or the Kyushu University criteria, as well as HCC, could have an acceptable long-term outcome.

Original language	English
Pages (from-to)	2475-2476
Number of pages	2
Journal	Anticancer research
Volume	35
Issue number	4
Publication status	Published - Apr 1 2015

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Fingerprint Dive into the research topics of 'Long-term outcome of living-donor liver transplantation for combined hepatocellular-cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this

Long-term outcome of living-donor liver transplantation for combined hepatocellular-cholangiocarcinoma. / Itoh, Shinji; Ikegami, Toru; Yoshizumi, Tomoharu; Wang, Huanlin; Takeishi, Kazuki; Harimoto, Norifumi; Yamashita, Yo Ichi; Kawanaka, Hirofumi; Aishima, Shinichi; Shirabe, Ken; Maehara, Yoshihiko.

In: Anticancer research, Vol. 35, No. 4, 01.04.2015, p. 2475-2476.

Research output: Contribution to journal › Article › peer-review

Itoh, Shinji ; Ikegami, Toru ; Yoshizumi, Tomoharu ; Wang, Huanlin ; Takeishi, Kazuki ; Harimoto, Norifumi ; Yamashita, Yo Ichi ; Kawanaka, Hirofumi ; Aishima, Shinichi ; Shirabe, Ken ; Maehara, Yoshihiko. / Long-term outcome of living-donor liver transplantation for combined hepatocellular-cholangiocarcinoma. In: Anticancer research. 2015 ; Vol. 35, No. 4. pp. 2475-2476.

@article{d5b0df034d6145e1ad2d38b4d95dc608,

title = "Long-term outcome of living-donor liver transplantation for combined hepatocellular-cholangiocarcinoma",

abstract = "Background/Aim: Combined hepatocellular-cholangio carcinoma (cHC-CC) is found unexpectedly in explanted or resected liver specimens. The current study evaluated the longterm outcomes of living-donor liver transplantation (LDLT) between patients with cHC-CC and hepatocellular carcinoma (HCC). Patients and Methods: We performed 178 LDLT including 8 patients of pathologically and immunohistochemically diagnosed cHC-CC who all under went LDLT with a preoperative diagnosis of HCC by ima ging study. Results: Out of the 8 patients, 6 were within the Milan criteria and all were within the Kyushu University criteria. The 1-, 5- and 10-year overall survival (OS) and disease-free survival (DFS) rates after LDLT for patients with cHC-CC were 87.5, 72.9 and 48.6% and 85.7, 85.7 and 85.7%, respectively. The OS and DFS between patients with cHC-CC and HCC were not statistically different. Conclusion: LDLT for patients with cHC-CC using the Milan criteria or the Kyushu University criteria, as well as HCC, could have an acceptable long-term outcome.",

author = "Shinji Itoh and Toru Ikegami and Tomoharu Yoshizumi and Huanlin Wang and Kazuki Takeishi and Norifumi Harimoto and Yamashita, {Yo Ichi} and Hirofumi Kawanaka and Shinichi Aishima and Ken Shirabe and Yoshihiko Maehara",

year = "2015",

month = apr,

day = "1",

language = "English",

volume = "35",

pages = "2475--2476",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "4",

}

TY - JOUR

T1 - Long-term outcome of living-donor liver transplantation for combined hepatocellular-cholangiocarcinoma

AU - Itoh, Shinji

AU - Ikegami, Toru

AU - Yoshizumi, Tomoharu

AU - Wang, Huanlin

AU - Takeishi, Kazuki

AU - Harimoto, Norifumi

AU - Yamashita, Yo Ichi

AU - Kawanaka, Hirofumi

AU - Aishima, Shinichi

AU - Shirabe, Ken

AU - Maehara, Yoshihiko

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background/Aim: Combined hepatocellular-cholangio carcinoma (cHC-CC) is found unexpectedly in explanted or resected liver specimens. The current study evaluated the longterm outcomes of living-donor liver transplantation (LDLT) between patients with cHC-CC and hepatocellular carcinoma (HCC). Patients and Methods: We performed 178 LDLT including 8 patients of pathologically and immunohistochemically diagnosed cHC-CC who all under went LDLT with a preoperative diagnosis of HCC by ima ging study. Results: Out of the 8 patients, 6 were within the Milan criteria and all were within the Kyushu University criteria. The 1-, 5- and 10-year overall survival (OS) and disease-free survival (DFS) rates after LDLT for patients with cHC-CC were 87.5, 72.9 and 48.6% and 85.7, 85.7 and 85.7%, respectively. The OS and DFS between patients with cHC-CC and HCC were not statistically different. Conclusion: LDLT for patients with cHC-CC using the Milan criteria or the Kyushu University criteria, as well as HCC, could have an acceptable long-term outcome.

AB - Background/Aim: Combined hepatocellular-cholangio carcinoma (cHC-CC) is found unexpectedly in explanted or resected liver specimens. The current study evaluated the longterm outcomes of living-donor liver transplantation (LDLT) between patients with cHC-CC and hepatocellular carcinoma (HCC). Patients and Methods: We performed 178 LDLT including 8 patients of pathologically and immunohistochemically diagnosed cHC-CC who all under went LDLT with a preoperative diagnosis of HCC by ima ging study. Results: Out of the 8 patients, 6 were within the Milan criteria and all were within the Kyushu University criteria. The 1-, 5- and 10-year overall survival (OS) and disease-free survival (DFS) rates after LDLT for patients with cHC-CC were 87.5, 72.9 and 48.6% and 85.7, 85.7 and 85.7%, respectively. The OS and DFS between patients with cHC-CC and HCC were not statistically different. Conclusion: LDLT for patients with cHC-CC using the Milan criteria or the Kyushu University criteria, as well as HCC, could have an acceptable long-term outcome.

UR - http://www.scopus.com/inward/record.url?scp=84928386189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928386189&partnerID=8YFLogxK

M3 - Article

C2 - 25862916

AN - SCOPUS:84928386189

VL - 35

SP - 2475

EP - 2476

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -